




The relative strengths and weaknesses of Royalty Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Royalty Pharma plc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 150% points. The greatest weakness of Royalty Pharma plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is 270%, being 40% points above the market average of 229%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	1,528,091	Assets	19,620,780
Cost of Goods Sold	0	Liabilities	9,905,841
Intangible Assets	924,634	Expenses	818,675
Liabilities, Current	636,211	Revenues	2,378,193
Liabilities, Non-Current	8,691,760	Stockholders Equity	9,714,939
Other Assets	17,168,055	Net Income	1,324,192
Other Compr. Net Income	0	Comprehensive Net Income	1,324,192
Other Expenses	-206,806	BaseVar	16,479,408
Other Liabilities	577,870	ECR before LimitedLiability	152%
Other Net Income	-235,326	Economic Capital Ratio	270%
Other Revenues	2,378,193		
Property and Equipment	0		
Research and Development	452,000		
Selling, General and Administrative Expense	573,481		